5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | NEUTRAL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.20▼ | 1.20▼ | 1.21▼ | 1.18▲ | 1.23▼ |
MA10 | 1.20▼ | 1.20▼ | 1.19▲ | 1.19▼ | 1.20▼ |
MA20 | 1.20▼ | 1.19▲ | 1.18▲ | 1.27▼ | 1.44▼ |
MA50 | 1.20▼ | 1.19▼ | 1.19▲ | 1.27▼ | 1.99▼ |
MA100 | 1.19▼ | 1.19▲ | 1.23▼ | 1.51▼ | 2.65▼ |
MA200 | 1.19▼ | 1.24▼ | 1.27▼ | 1.92▼ | 6.47▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.001▼ | 0.000▲ | 0.003▲ | -0.008▼ | 0.016▲ |
RSI | 38.676▼ | 49.573▼ | 49.943▼ | 44.672▼ | 39.997▼ |
STOCH | 43.056 | 25.499 | 63.040 | 31.571 | 45.847 |
WILL %R | -100.000▼ | -61.111 | -50.000 | -71.429 | -64.277 |
CCI | -114.074▼ | -38.889 | 33.143 | -28.659 | -57.236 |
Thursday, June 12, 2025 08:30 AM
A month has gone by since the last earnings report for Allogene Therapeutics (ALLO). Shares have added about 52.2% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
|
Monday, June 02, 2025 12:41 PM
On June 1, Allogene Therapeutics Inc. (NASDAQ:ALLO) presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma/RCC during an oral ...
|
Sunday, June 01, 2025 07:50 AM
“ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma,” said Zachary ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
08/07/25 | 1.18 | 1.245 | 1.18 | 1.19 | 3,457,942 |
07/07/25 | 1.22 | 1.23 | 1.13 | 1.16 | 1,970,993 |
03/07/25 | 1.20 | 1.21 | 1.17 | 1.19 | 1,384,912 |
02/07/25 | 1.19 | 1.29 | 1.18 | 1.20 | 4,810,250 |
01/07/25 | 1.13 | 1.23 | 1.11 | 1.18 | 2,211,580 |
30/06/25 | 1.18 | 1.19 | 1.12 | 1.13 | 2,137,898 |
27/06/25 | 1.20 | 1.23 | 1.17 | 1.18 | 5,178,774 |
26/06/25 | 1.23 | 1.245 | 1.16 | 1.20 | 3,129,087 |
25/06/25 | 1.26 | 1.275 | 1.21 | 1.24 | 1,460,855 |
24/06/25 | 1.22 | 1.29 | 1.20 | 1.25 | 3,013,406 |
|
|
||||
|
|
||||
|
|